Sponsors (6)
The bill aims to improve early detection and equity in preeclampsia care—particularly for Medicaid enrollees and high‑risk groups—by clarifying eligible diagnostics and speeding federal help, but it could raise public and Medicaid spending, create uneven state-by-state access, and strain underfunded providers if additional resources are not provided.
Pregnant people — especially those on Medicaid/CHIP — gain clearer, faster access to early preeclampsia screening and advanced diagnostic options (including FDA-cleared biomarkers and CLIA high-complexity tests), improving timely diagnosis and care.
Black women and other high‑risk groups could see improved maternal outcomes if the bill's findings prompt equity‑focused interventions and targeted prevention, potentially reducing maternal deaths and preterm births.
Identifying preeclampsia risk factors and long‑term cardiovascular risks encourages better postpartum monitoring and prevention, which may lower long‑term health care costs for affected women.
Highlighting a more than $2 billion annual economic burden and expanding focus on preeclampsia could prompt increased federal or state spending to address the problem, raising taxpayer costs.
If states adopt coverage of advanced biomarker tests or costly lab‑developed diagnostics without clear cost‑effectiveness, Medicaid program spending could rise, straining state budgets and federal matching funds.
States might interpret guidance differently, producing uneven access across states to preeclampsia screening and diagnostics and thereby worsening geographic inequities in care.
Based on analysis of 3 sections of legislative text.
Directs HHS to issue guidance and timely technical assistance to States on Medicaid/CHIP coverage of early preeclampsia screening and detection tests, including certain biomarker and lab-developed tests.
Official title: To amend title XIX of the Social Security Act to require the Secretary of Health and Human Services to issue guidance to States on which tests for the screening and early detection of preeclampsia may be covered under the Medicaid program and the Children's Health Insurance Program.
Introduced May 29, 2026 by Thomas Kean · Last progress May 29, 2026
Requires the Department of Health and Human Services to issue guidance and provide technical assistance to State Medicaid and CHIP programs on coverage of early screening, detection, and management tests for preeclampsia, including advanced biomarker tests and certain laboratory-developed tests. The guidance must be published within 180 days of enactment and HHS must respond to State requests for technical assistance within 30 days; States are not required to request assistance to receive Federal support. The goal is to promote earlier detection and evidence-based management of preeclampsia, reduce racial disparities in maternal outcomes, and clarify which tests may be furnished as Medicaid/CHIP medical assistance so States and managed care organizations can expand or standardize coverage where appropriate.